Stay updated on ABP 798 vs. Rituximab in RA Clinical Trial
Sign up to get notified when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.

Latest updates to the ABP 798 vs. Rituximab in RA Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page revision label was updated to v3.5.4. This indicates a minor system/template update and does not change study information.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page’s footer/update metadata was bumped to a new revision version (v3.5.3 instead of v3.5.2), reflecting a technical site/version change without modifying the listed study information.SummaryDifference0.0%

- Check37 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision: v3.5.0 deployed to replace v3.4.3. No substantive changes to the study details, eligibility criteria, or results are reflected on the page.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 to reflect a new page version. No study details were changed.SummaryDifference0.0%

- Check102 days agoChange DetectedRevision: v3.4.2 is now shown as the site version, and the previous government funding lapse notice has been removed (v3.4.1). These are minor housekeeping changes and do not modify the study details or user-visible trial information.SummaryDifference0.3%

Stay in the know with updates to ABP 798 vs. Rituximab in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.